Navigation Links
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Date:1/18/2012

uct portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda also plans to consolidate its R&D sites to ensure ongoing support for all marketed products and support development and global registration of new products throughout the combined footprint. Takeda will invest strongly in R&D focused on core therapeutic areas, while effectively deploying both internal and external resources to create innovative drugs and transform treatment paradigms. The integrated R&D organization aims to support Takeda's global vision of bringing innovative products to address patients' needs by maximizing efficiency, driving standardization, optimizing resource utilization and driving productivity.  

To meet its goals, Takeda plans the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of workforce in the United States, primarily within Takeda Pharmaceuticals North America. The necessary cost for this plan is estimated approximately Yen 70 billion in total during fiscal 2011 - 2015. During this period, Takeda will achieve cost synergies of approximately Yen 200 billion. The cost synergy in Europe estimated in fiscal 2014 is now Yen 40 billion which is 10 billion greater than the original forecast announced in May 2011. Takeda plans a reduction of the Takeda global workforce by approximately 2,800 (2,100 mainly in Europe and 700 in the U.S.) positions by the end of fiscal 2015 across the functions of R&D, commercial, operations and G&A.

Employees affected by the measures will be offered appropriate guidance and support in accordance with Takeda's corpora
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
2. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
3. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
5. Takeda Completes Acquisition and Names New CEO of Nycomed
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
9. Takeda to Acquire Nycomed
10. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
11. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... This report analyzes the worldwide markets for ADME-Toxicology ... (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate ... Japan , Europe , ... estimates and forecasts are provided for the period 2014 through ... markets. Market data and analytics are derived from primary and ...
(Date:4/20/2015)... 20, 2015 This report analyzes the worldwide ... Million. The report provides separate comprehensive analytics for the ... , and Rest of World. Annual estimates and ... Also, a seven-year historic analysis is provided for these ... and secondary research. Company profiles are primarily based on ...
(Date:4/20/2015)...  Johnson & Johnson (NYSE: JNJ ) will ... investment community beginning at 8:30 a.m. (Eastern Time) on ... in New Brunswick, New Jersey ... Paul Stoffels , M.D., Worldwide Chairman Pharmaceuticals, and Chief ... Pharmaceuticals will host the meeting. Dominic Caruso , ...
Breaking Medicine Technology:World ADME-Toxicology Testing Industry 2World ADME-Toxicology Testing Industry 3World ADME-Toxicology Testing Industry 4World ADME-Toxicology Testing Industry 5World ADME-Toxicology Testing Industry 6World ADME-Toxicology Testing Industry 7World ADME-Toxicology Testing Industry 8World ADME-Toxicology Testing Industry 9World ADME-Toxicology Testing Industry 10World ADME-Toxicology Testing Industry 11World ADME-Toxicology Testing Industry 12World ADME-Toxicology Testing Industry 13World ADME-Toxicology Testing Industry 14World ADME-Toxicology Testing Industry 15World ADME-Toxicology Testing Industry 16World ADME-Toxicology Testing Industry 17World ADME-Toxicology Testing Industry 18World ADME-Toxicology Testing Industry 19World Medical Equipment Rental and Leasing Industry 2World Medical Equipment Rental and Leasing Industry 3World Medical Equipment Rental and Leasing Industry 4World Medical Equipment Rental and Leasing Industry 5World Medical Equipment Rental and Leasing Industry 6World Medical Equipment Rental and Leasing Industry 7
... (NASDAQ: CYBX ), a global leader in medical ... that the U.S. Food and Drug Administration ("FDA") approved a ... by patients who have the VNS Therapy System. ... scanners with magnetic field strengths of 3.0 and 1.5 Tesla; ...
... WASHINGTON, Oct. 31, 2011 Many of the ... the American College of Gastroenterology,s (ACG) 76th Annual ... Conference Center at the National Harbor to review ... of digestive diseases and clinical practice management. ...
Cached Medicine Technology:Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems 2Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems 3Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 2Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 3Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 4Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 5Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 6Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting 7
(Date:4/20/2015)... April 20, 2015 Florida Hospital at ... three prestigious awards from Select Medical, during the annual ... Friday, April 10th. Chief Operating Officer, Debi Martoccio, received ... She was one of six recipients out of 113 ... Dinney Humanitarian Award for the contributions to the community ...
(Date:4/20/2015)... 20, 2015 “ Verus ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... variety of purposes. , According to CNET, at least ... in 2013. It’s unfortunate that smartphones break so easily, ...
(Date:4/20/2015)... Hill, FL (PRWEB) April 20, 2015 ... health issue in the United States for decades. ... lost productivity, healthcare costs and property damage each year, ... its victims, as well as their families and loved ... Suncoast Rehabilitation Center is dedicated to raising awareness ...
(Date:4/20/2015)... Plainsboro, NJ (PRWEB) April 20, 2015 ... Centers of America and editor-in-chief of OncologyLive magazine ... women with BRCA-mutated advanced ovarian cancer is too restrictive ... In an interview featured on OncLive.com, Maurie Markman, M.D., ... high-grade serous ovarian cancer who do not test positive ...
(Date:4/20/2015)... Catalent, the leading global provider ... drugs, biologics and consumer health products, today announced ... as part of a consortium looking to evaluate, ... nano-pharmaceutical virosome-based vaccine candidates. , Currently, 90% of ... of the consortium is to develop a scalable ...
Breaking Medicine News(10 mins):Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3Health News:Attractive and Durable Phone Cases were Featured on NewsWatch Television 2Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 2Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 3Health News:Drunk Driving Repeat Offenders: Suncoast Rehab Center Observes Alcohol Awareness Month by Advocating for Preventive Measures Against DUIs 4Health News:Recent FDA Approval of Ovarian Cancer Treatment Is Too Restrictive, Specialist in Gynecologic Malignancies Says in OncLive® Article 2Health News:Catalent Awarded Grant as Part of Vaccine Research Consortium 2Health News:Catalent Awarded Grant as Part of Vaccine Research Consortium 3Health News:Catalent Awarded Grant as Part of Vaccine Research Consortium 4Health News:Catalent Awarded Grant as Part of Vaccine Research Consortium 5
... prostate cancer was extremely dangerous, men over 75, may ... prostatectomy or radiation does help to eradicate ... is often affected because of resulting urinary incontinence and ... Hoffman, an associate professor of medicine at the University ...
... relief to the anti-quota camp, the Supreme Court Friday ... 10 percent seats on an all-India basis// for scheduled ... for the 2006-07 academic year. ,A bench of ... the submissions of Additional Solicitor General Gopal Subramaniam that ...
... The official death toll that has been reported in Angola ... unusually high mortality rate and it is expected to affect ... ,Since the first report of the outbreak in ... been reported. ,Uige, a city 300km northeast of ...
... distinction of accounting for 25 percent of global maternal ... to promote safe motherhood. // ,The Federation ... marked the successful conclusion of its first such effort ... by gynaecologist Shirin Venkat along the Ganges. ...
... to house some of Europe’s biggest Poultry farms, has been ... H7N3 Strain of bird flu on three of its farms. ... culling of birds, and have ensured its safe disposal, cleansing ... have issued this statement., ,A restricted zone extending nearly ...
... a Nobel laureate hopes to manufacture plentiful anti-flu drugs at ... Corey has work out the method while relaxing at home ... the drug and given it to World Health Organization to ... (shikimic acid) for the production cycle is a compound extracted ...
Cached Medicine News:Health News:Supreme Court Quashed Reservation Quotas For PG Medical Courses 2Health News:Death from Cholera Rises in Angola 2Health News:Doctors Join Hands To Spread Awareness Against Maternal Mortality 2
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
Latex agglutination slide test for the qualitative and semi-qualitative detection of antinuclear antibodies to aid in the diagnosis of systemic lupus erthyematosus....
Color-enhanced slide test for the rapid qualitative and semi-quantitative detection of antibodies to streptococcal extracellular antigens in serum, plasma and peripheral blood....
Latex agglutination slide test to aid in the identification of Staphylococcus aureus colonies from culture media....
Medicine Products: